viewTRACON Pharmaceuticals

TRACON Pharmaceuticals files ENVASARC protocol with FDA to study envafolimab as sarcoma treatment

Its Investigational New Drug application calls for studying two cohorts of 80 patients each, including envafolimab in combination with immunotherapy Yervoy

San Diego company expects to initiate enrollment in the ENVASARC trial at 25 US sites in the second half of 2020

TRACON Pharmaceuticals Inc (NASDAQ:TCON) has filed the pivotal ENVASARC protocol with the US Food and Drug Administration to study single-domain antibody envafolimab as a treatment for sarcoma. 

The Investigational New Drug (IND) application cross-references the open envafolimab IND maintained by TRACON’s corporate partners 3D Medicines and Alphamab Oncology, TRACON said in a statement Thursday.

The company previously reported results of a May 8 teleconference with the FDA whereby the agency agreed with TRACON’s proposals regarding key elements of the ENVASARC trial for envafolimab in the soft tissue sarcoma subtypes of undifferentiated pleomorphic sarcoma and myxofibrosarcoma.

READ: TRACON Pharmaceuticals to host key opinion leader webinar on envafolimab for the treatment of sarcoma on July 17

San Deigo-based TRACON said it expects to initiate enrollment in the ENVASARC trial at 25 sites in the US in the second half of 2020.

Key elements for the ENVASARC pivotal trial include:

  • Multi-center, open-label, randomized, non-comparative, parallel cohort study.
  • Eligible patients will have received one or two prior cancer therapies, but no prior immune checkpoint inhibitor therapy.
  • Planned total enrollment of 160 patients, with 80 patients enrolled into cohort A of treatment with single-agent envafolimab and 80 patients enrolled in cohort B of treatment with envafolimab and Yervoy.
  • The primary endpoint of objective response rate with the duration of response a key secondary endpoint.
  • Open-label format with a blinded independent central review of efficacy endpoint data.

TRACON's stock recently traded up by 2% to $2.01 a share in New York.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: TRACON Pharmaceuticals

Price: 5.01 USD

Market: NASDAQ
Market Cap: $66.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...


TRACON Pharmaceuticals approved by the FDA to begin sarcoma cancer therapy...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the FDA has given the go-ahead for its human trial of envafolimab for sarcoma cancer. Theuer says it expects to start enrolling patients in the trial at 25 sites in the US in the fourth quarter of 2020.

on 08/18/2020

2 min read